Drug research

Hypericin

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as HyBryte; SGX301; SGX302

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaNCT05380635	Soligenix	Phase 2	Completed	2022-08-16Actual
Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190	Soligenix	Phase 2	Completed	2025-10-22Actual
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLNCT06149247	Soligenix	Phase 2	Completed	2024-05-31Actual
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLNCT06470451	Soligenix	Phase 3	Terminated	2026-05-22Actual

SoligenixCompletedPrimary completion: 2022-08-16 · Actual

Trial details

SoligenixCompletedPrimary completion: 2025-10-22 · Actual

Trial details

SoligenixCompletedPrimary completion: 2024-05-31 · Actual

Trial details

SoligenixTerminatedPrimary completion: 2026-05-22 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.